Data Sheet (Cat.No.T11521)

TargetMol

GW 766994

Chemical Properties



CAS No. : 408303-43-5

Formula: C21H24Cl2N4O3

Molecular Weight: 451.35

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	GW 766994 is a selective, orally active CCR3 (chemokine receptor-3) antagonist (Ki=13.8 nM) with anti-inflammatory effects, suitable for studying asthma and eosinophilic bronchitis.
Targets(IC50)	CCR
In vitro	CCL11 treatment leads to the activation of CDK5 and GSK3β in hippocampal neurons, increased phosphorylation of tau protein at multiple sites, significantly elevated secretion of Aβ1-42, and a marked reduction in dendritic spine density. These effects were blocked by the CCR3-specific antagonist GW 766994 (10 μM) [2].

Solubility Information

Solubility	DMSO: 40 mg/mL (88.62 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween-80+45% Saline: 2 mg/mL (4.43 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	2.2156 mL	11.0779 mL	22.1558 mL
5 mM	0.4431 mL	2.2156 mL	4.4312 mL
10 mM	0.2216 mL	1.1078 mL	2.2156 mL
50 mM	0.0443 mL	0.2216 mL	0.4431 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Neighbour H, et al. Safety and efficacy of an oral CCR3 antagonist in patients with asthma and eosinophilic bronchitis: a randomized, placebo-controlled clinical trial. Clin Exp Allergy. 2014 Apr;44(4):508-16.
Zhu C, et al. Targeting CCR3 to Reduce Amyloid-β Production, Tau Hyperphosphorylation, and Synaptic Loss in a Mouse Model of Alzheimer's Disease. Mol Neurobiol. 2017 Dec;54(10):7964-7978.